Other substances

Torin 2

A mammalian target of rapamycin inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Torin 2 is a pyridoquinoline inhibitor of mammalian target of rapamycin complex 1 (mTORC1) with protentional antineoplastic activities. It was suggested to inhibit SARS-CoV-2 infection via mTORC1 inhibition (although by an unknown mechanism) (ChEBI; Mullen et al., 2021).

Torin 2 on PubChem

C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication Preprint Screening	VERO E6 cell cultures			Jun/25/2020
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition Small molecule In vitro	Vero cells; human lung air-liquid interface cultures; SARS-CoV-2 isolate USA-WA1/2020	12.12	Inhibited SARS-CoV-2 replication in Vero cells, possibly through mTORC1 inhibition.	Mar/25/2021
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication Small molecule In vitro Mechanism	Vero E6 cells; Calu-3 cells; HEK293-ACE2 cells; HeLa-ACE2 cells; A549-ACE2 cells; human-induced pluripotent stem-cell-derived cardiomyocyte; SARS-CoV-2 isolate USA-WA1/2020	8.11	Inhibited SARS-CoV-2 infection in Vero E6 cells. It displayed some cytotoxicity, however.	Mar/17/2021

Export (.csv)